Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model

Placental transfer of tofacitinib in the ex vivo dual-side human placenta perfusion model

Tofacitinib is a small molecule Janus kinase (JAK) inhibitor, introduced to the European market in 2017, for the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. In the treatment of women with autoimmune diseases, pregnancy is a relevant issue, as such diseases typicall...

Full description

Bibliographic Details
Main Authors: Gaby A.M. Eliesen, Milou Fransen, Hedwig van Hove, Petra H.H. van den Broek, Rick Greupink
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Research in Toxicology
Subjects:
Cotyledon perfusion
Drug disposition
Drug safety
Reproductive toxicology
Fetal drug exposure
Pharmacokinetics
Online Access:http://www.sciencedirect.com/science/article/pii/S2666027X24000021

Internet

http://www.sciencedirect.com/science/article/pii/S2666027X24000021

Similar Items